We are live on ! Find out more
VRX

VALEANT PHARMACEUTICALS INTL
VRX

Delisted

VRX was delisted on the 27th of September, 2010.

Back to rankings

1 hedge funds and large institutions have $1.26M invested in VALEANT PHARMACEUTICALS INTL in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

90% less capital invested

Capital invested by funds: $13M → $1.26M (-$11.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CG
Colony Group
Massachusetts
+$27.1K

Top Sellers

Rank Fund Capital Flow
1
SAM
Shikiar Asset Management
New York
-$6.97M
2
PIM
Perkins Investment Management
Illinois
-$4.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Colony Group
Massachusetts
$1.26M +$27.1K +122 +2%
SAM
2
Shikiar Asset Management
New York
– -$6.97M -35,080 Closed
PIM
3
Perkins Investment Management
Illinois
– -$4.97M -25,000 Closed

VRX Hedge Fund Activity: Q2 2015 in Review

1 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q2 2015, worth a combined $1.26M — down 90% from $13M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of VRX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Colony Group, adding an estimated $27.1K. The largest seller was Shikiar Asset Management, exiting entirely with an estimated $6.97M sold.

  • 1 institutional investor held VALEANT PHARMACEUTICALS INTL (VRX) as of Q2 2015, down from 3 in Q1 2015.
  • Funds reported $1.26M of VALEANT PHARMACEUTICALS INTL stock for Q2 2015, down 90% quarter-over-quarter.
  • 0 funds opened new VALEANT PHARMACEUTICALS INTL positions in Q2 2015 and 2 closed out, a net change of -2 holders.
  • The largest VALEANT PHARMACEUTICALS INTL buyer in Q2 2015 was Colony Group, an estimated $27.1K added.
  • The largest VALEANT PHARMACEUTICALS INTL seller in Q2 2015 was Shikiar Asset Management, an estimated $6.97M sold.

Based on aggregated 13F filings for Q2 2015.